KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) EBITDA Margin (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of EBITDA Margin data on record, last reported at 9.63% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1293.0% year-over-year to 9.63%; the TTM value through Dec 2025 reached 20.84%, down 451.0%, while the annual FY2025 figure was 20.84%, 451.0% down from the prior year.
  • EBITDA Margin reached 9.63% in Q4 2025 per EW's latest filing, down from 19.77% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 45.99% in Q4 2022 and bottomed at 9.63% in Q4 2025.
  • Average EBITDA Margin over 5 years is 28.53%, with a median of 28.05% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: skyrocketed 5774bps in 2021, then plummeted -1860bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 28.16% in 2021, then skyrocketed by 63bps to 45.99% in 2022, then tumbled by -40bps to 27.38% in 2023, then dropped by -18bps to 22.56% in 2024, then crashed by -57bps to 9.63% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 9.63% in Q4 2025, 19.77% in Q3 2025, and 26.84% in Q2 2025.